Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.
Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.
PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.